Could setanaxib boost keytruda against head and neck cancer?
Disease control
Completed
This Phase 2 trial tested whether adding setanaxib (an experimental oral drug) to the standard immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with recurrent or metastatic squamous cell carcinoma of the head and neck. 55 adults whose cancer…
Phase: PHASE2 • Sponsor: Calliditas Therapeutics Suisse SA • Aim: Disease control
Last updated Jun 26, 2026 13:14 UTC